Articles

Research News

Published on 17 October 2017

HIV patients will accept generic treatments

Human immunodeficiency virus (HIV) patients in high-income countries are likely to accept the introduction of generic antiretroviral (ARV) drugs, according to a study carried out by researchers in Ireland [1]....

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0604.041

3.527 views

Read more →

Abstracted Scientific Content

Published on 17 October 2017

A comparison of European and US generic drug markets

Submitted: 19 June 2017; Revised: 5 September 2017; Accepted: 6 September 2017; Published online first: 19 September 2017 Introduction Comparative research on the European and US generic drug markets based...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0604.043

32.859 views

Read more →

Perspective

Published on 17 October 2017

40th anniversary of essential medicines: a loud call for improving its access

Author byline as per print journal: Mohammad Bashaar, PhD; Professor Mohamed Azmi Hassali, PhD; Fahad Saleem, PhD Abstract: The soaring costs of medicine are a global dilemma. It was hoped that the...

Author(s): Fahad Saleem, Mohammad Bashaar, Professor Mohamed Azmi Hassali, PhD

access barriers, affordability, essential medicines, medicine prices

DOI: 10.5639/gabij.2017.0604.036

10.012 views

Read more →

Letters to the Editor

Published on 02 October 2017

Clear naming, traceability of biological medicines will protect patients

Author byline as per print journal: Adjunct Professor Valderilio Feijó Azevedo, MD, PhD, MBA; Associate Professor Brian Bressler, MD, MS, FRCPC; Madelaine A Feldman, MD, FACR; Professor Alejandro Mercedes, MD Abstract:...

Author(s): Alejandro Mercedes, MD, Associate Professor Valderilio Feijó Azevedo, MD, PhD, MSc, Brian Bressler, MD, Madelaine A Feldman, MD, FACR

Biological Qualifier (BQ), biosimilars, International Nonproprietary Name (INN), naming, pharmacovigilance, World Health Organization (WHO)

DOI: 10.5639/gabij.2017.0604.031

5.525 views

Read more →

Published on 27 September 2017

2017/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2017, Issue 3 Commentary Patent expiry and costs for anti­cancer medicines for clinical use Original Research A survey of Australian prescribers’ views...

2.563 views

Read more →

Editor's Letter

Published on 27 September 2017

Latest features in GaBI Journal, 2017, Issue 3

It is clear that greater use of generics and biosimilars could greatly decrease healthcare costs and thereby increase availability of important medicines. It is equally clear that these potential savings...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2017.0603.020

3.275 views

Read more →

Research News

Published on 27 September 2017

Healthcare professionals will accept generic HIV treatments

Healthcare professionals working with HIV patients in high-income countries are likely to accept the introduction of generic antiretroviral drugs (ARVs), according to a study carried out by researchers in Ireland...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0603.029

3.381 views

Read more →

Abstracted Scientific Content

Published on 27 September 2017

‘To prescribe generics is to play with the life of the patient’: misconceptions of generics in Guatemala

Submitted: 13 September 2017; Revised: 17 September 2017; Accepted: 18 September 2017; Published online first: 25 September 2017 Both pharmacists and doctors in Guatemala lack trust in generic medicines, according...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0603.028

4.090 views

Read more →

Pharma News

Published on 06 September 2017

Top developments in biosimilars during 2017

Submitted: 30 January 2018; Revised: 8 February 2018; Accepted: 12 February 2018; Published online first: 26 February 2018 The past year has once again been a busy one for the...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0701.008

11.616 views

Read more →

Guidelines

Published on 06 September 2017

Biosimilars in Germany: guidance of the Drug Commission of the German Medical Association

Abstract: Biosimilars have been available in Europe for more than 10 years, but their adoption in Germany has not been very successful. As their pharmaceutical quality, efficacy (particularly in extrapolated...

Author(s): Professor Wolf-Dieter Ludwig, PhD, Stanislava Dicheva, PhD

biologicals, biosimilars, Germany, guidance, switching

DOI: 10.5639/gabij.2017.0604.037

15.726 views

Read more →

Original Research

Published on 06 September 2017

Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies

Introduction/Study objectives: Between March and May 2017, Pfizer conducted an internal global survey of 82 countries examining biosimilar pharmacy-mediated substitution to understand and benchmark the global policy landscape. Methods: Pfizer...

Author(s): Hannah Larkin, Judith Macdonald, Rebecca Lumsden, PhD

biosimilars, global, interchangeability, pharmacy, regulation, substitution

DOI: 10.5639/gabij.2017.0604.034

111.337 views

Read more →

Special Report

Published on 28 June 2017

Physician associations comment on FDA’s interchangeability guidance

Abstract: Comments from physician associations on the US Food and Drug Administration’s draft guidance on interchangeability of biosimilars are presented in this paper. Various issues were discussed; this paper highlights...

Author(s): GaBI Journal Editor

biosimilar, extrapolation, interchangeability, labelling, switching, US Food and Drug Administration (FDA)

DOI: 10.5639/gabij.2017.0603.024

6.625 views

Read more →